Chairman participated in China medical insurance chamber of commerce "innovation and development in China and the world"

On June 18-19, 2019, the medical insurance chamber of commerce successfully hosted the 2019 innovation and development BBS in China and the world during the 19th world pharmaceutical raw materials exhibition in Shanghai.Distinguished guests from the government, research institutes and the business community presented excellent speeches to the audience and received warm comments.Vice President tan shengcai attended the BBS and delivered the opening speech.Tan said that China's pharmaceutical industry, which concerns people's health, economic growth and social development, has developed rapidly and achieved remarkable results in recent years.Under the current background of sino-us trade frictions, uncertainties affecting the healthy development of the pharmaceutical industry are on the rise.The healthcare chamber of commerce is committed to providing high-level opportunities for regular exchanges, gathering all forces to analyze the new environment, new situation and new opportunities, and promoting exchanges and cooperation among enterprises, so as to promote China's development from a major pharmaceutical country to a great pharmaceutical country.

In the African market in the afternoon of June 18, special activities, general manager hai-ching liu Unicure pharmaceutical company in Nigeria, people partners f pharmaceutical company general manager tang yuk and sinosure trade Fan Chenyang underwriting department director, respectively, medical market analysis in Nigeria and west Africa, East Africa medicine market present situation and prospects, and African medicine trade risk analysis and management and so on has carried on the keynote.General manager liu haiqing pointed out that Africa has become the region with the highest investment growth rate in the world. As a big African country, Nigeria's economy has been developing continuously in recent years.He also Shared his company's experience in manufacturing and operating in Nigeria, suggesting that Chinese companies should group together and focus on developing industrial chains and industrial parks to avoid vicious competition.General manager tang yuzhong introduced the investment policy environment and current situation in East Africa, especially Ethiopia, as well as the existing problems.Director fan chenyang introduced the business types of China credit insurance and the development of pharmaceutical trade insurance business, and gave risk tips to the delegates to carry out African pharmaceutical trade.

General manager liu haiqing, general manager tang yuzhong and general manager wang yafeng, director of fosun collina Nigeria participated in the round table discussion.The three participants said that Chinese pharmaceutical enterprises have made great progress, but they still need to make great efforts to expand the African market. There is still a shortage of talents who are familiar with both English and medicine. Chinese enterprises need to strengthen the ability and level of solidarity and cooperation, and their soft power needs to be improved.In order to achieve differentiated competition with competitors, China should focus on channel construction, brand building and industrial chain improvement.

As the world's active pharmaceutical ingredients (China) one of the important supporting activities during the exhibition, healthcare chamber of commerce has 9 consecutive years of innovation and development of BBS in China and the world, for the domestic and foreign medical entrepreneurs, industry experts and relevant government departments to provide a high level of regular exchange opportunities, make we can from the industry's future development, the perspective of globalization strategy to keen insight and deeply analyze the Chinese and foreign medicine industry in the development of the new environment, new situation, keep the latest information, idea and wisdom into the enterprise and industry development, promote and deepen the exchanges and cooperation between Chinese and foreign pharmaceutical enterprises.